Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma.
about
The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin CancerPathways and therapeutic targets in melanomaTargeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyondFocused chemical genomics using zebrafish xenotransplantation as a pre-clinical therapeutic platform for T-cell acute lymphoblastic leukemiaUSP15 regulates SMURF2 kinetics through C-lobe mediated deubiquitination.An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition.The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFαProteomic profile and in silico analysis in metastatic melanoma with and without BRAF mutationBRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma modelGene expression profiling identifies microphthalmia-associated transcription factor (MITF) and Dickkopf-1 (DKK1) as regulators of microenvironment-driven alterations in melanoma phenotypeMITF in melanoma: mechanisms behind its expression and activity.Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.MITF Modulates Therapeutic Resistance through EGFR Signaling.Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy.Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells.Melanoma biomolecules: independently identified but functionally intertwined.Crosstalk between kinases and Nedd4 family ubiquitin ligases.MAPK pathway inhibition in melanoma: resistance three ways.Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma.Zebrafish: a new companion for translational research in oncology.Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy.MITF suppression by CH5552074 inhibits cell growth in melanoma cells.Glucose availability controls ATF4-mediated MITF suppression to drive melanoma cell growth.Modeling tandem AAG8-MEK inhibition in melanoma cells.A melanocyte lineage program confers resistance to MAP kinase pathway inhibition.Targeting invasive properties of melanoma cells.Molecular Pathways: Maintaining MAPK Inhibitor Sensitivity by Targeting Nonmutational Tolerance.Mechanisms of Drug Resistance in Melanoma.Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failureTargeting MITF in the tolerance-phaseOvercoming resistance to BRAF inhibitors.1-Benzyl-indole-3-carbinol is a highly potent new small molecule inhibitor of Wnt/β-catenin signaling in melanoma cells that coordinately inhibits cell proliferation and disrupts expression of microphthalmia-associated transcription factor isoform-MCollagen abundance controls melanoma phenotypes through lineage-specific microenvironment sensing.Fishing for cures: The alLURE of using zebrafish to develop precision oncology therapies.Microenvironment-Driven Dynamic Heterogeneity and Phenotypic Plasticity as a Mechanism of Melanoma Therapy Resistance.Smurfs in Protein Homeostasis, Signaling, and Cancer
P2860
Q26747247-0CA2F0CF-B048-4F05-AE6E-A8C69BDEAAD1Q26865736-1DBA56ED-43A6-4131-9C47-F3225634FD71Q27026323-53CD9D2D-1D2B-408D-A0B9-C12CBC9164C7Q28542972-C4EE267D-2501-4014-968B-AC2916D27D55Q30666768-24924F82-A97A-4161-8697-424E5C1277DAQ33769541-BC2AFB52-C2FD-494D-897C-296E4F522DF1Q34287452-1EFEEC9C-BC2F-4784-84E5-8F9D7BC42179Q34599527-79AD7BD6-CA3A-4F3A-A911-25B7AF98EA6CQ35090029-BA85719B-4E77-4AE2-ACBD-83FC4E3B1FE1Q35147858-F4AAD17C-CA03-4E4D-8DF4-FC729391EFBBQ35187734-6A2CC079-F329-481A-BD03-3B15ABC84A0BQ35596369-2F913136-CE00-412D-96CE-E8B04C4DCA1DQ35738447-4CA0FC76-D8F0-4C03-B0D5-D3B257447096Q36698266-B547384D-B5BD-4E19-B4DB-CF4402CC4233Q36774894-FEF8C139-946E-44BF-85E6-3FB0430E5A9EQ38143977-B82789C9-0E2C-4373-A510-6D8192F4BA7DQ38181338-C618F191-1D09-43E4-95D9-4792E330D906Q38238597-BC65FE7D-5FD5-4F78-9F68-558205318FFFQ38241987-B642565B-6A96-4405-A02E-604EB3B27B36Q38312265-48C57C0E-ECDB-4DCA-BBE8-23D0522E727DQ38394400-5829D8C4-A77A-443A-B27A-0D74E4551D70Q38705893-A985FA6C-0FB8-4905-BFF4-EE6DE734B91AQ38852351-1D30DBB1-9A9C-4CAE-8450-C5D580114959Q39014901-2746F9E7-938F-4040-AE1E-9E161C488951Q39067618-75E7A8CD-E461-4691-BD12-C4B496799ACEQ39135139-3DE3D55D-3659-4E7D-B41D-E874EC3F208EQ39164873-B8C7010C-DCB8-41AC-ADCE-920D5F29E323Q39169776-C63557F5-D820-4EF4-8FBB-A8C97FAB7386Q41198115-BA56BC97-B33F-44C9-8977-62B7ACF486EBQ42317513-F887E2D9-2AE5-45FD-837E-1B35CCAB736BQ43298157-364BD0F1-B579-411C-88B8-F39CF7179597Q46030038-9A6E76FA-607F-4F03-8D70-A9DA60828B1CQ52353746-CE294D1D-9F22-40DB-BA13-886107FDFB8DQ52703978-C1AB0C06-C313-472C-BC60-02BA3CD3EC10Q55424318-EE68B0F9-3F67-4429-93D2-A1F46EB354A2Q58803474-D7FDC3C6-D5AA-4103-868C-47FD50018C48
P2860
Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma.
@ast
Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma.
@en
type
label
Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma.
@ast
Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma.
@en
prefLabel
Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma.
@ast
Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma.
@en
P2093
P2860
P50
P356
P1476
Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma.
@en
P2093
Anna Chapman
Jennifer Ferguson
Robert Hayward
P2860
P356
10.1093/JNCI/DJS471
P407
P577
2012-12-17T00:00:00Z